Vimta Labs Limited · NSE:VIMTALABS
Vimta Labs — Q2 FY27 Earnings Presentation
32 slides from Vimta Labs's earnings presentation, Oct 30, 2026
Slide 1: SUJANI VASIREDDI Date:
Digitally signed by SUJANI SUJANI VASIREDDI VASIREDDI Date: 2026.10.30 13:22:41 +05'30'
Slide 2: Investor Presentation Q2 & H1 FY27
INVESTOR PRESENTATION Q2 & H1 FY27 1
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Table Of Contents
Table Of • Q2 & H1 FY27 Earnings Contents • Company Overview • Industry Landscape • Our Competitive Advantage • Way Forward 3
Slide 5: Q2 & H1 FY27 Earnings
Q2 & H1 FY27 Earnings Section • Q2 & H1 FY27 Highlights 01 • • Key Metrics: Q2 & H1 FY27 Profit & Loss Statement • Financial Track Record • Shareholding Pattern 4
Slide 6: Q2 FY27 Highlights
Q2 FY27 Highlights Rs 1,149 Mn Rs 408 Mn Rs 275 Mn Margin 35.5% Total Income EBITDA PBT Rs 4.6 Rs 92 Mn Rs 206 Mn Margin 17.9% CAPEX (Cash EPS PAT Outflow) 5
Slide 7: H1 FY27 Highlights
H1 FY27 Highlights Rs 2,278 Mn Rs 819 Mn Rs 559 Mn Margin 36.0% Total Income EBITDA PBT Rs 9.3 Rs 701 Mn Rs 417 Mn Margin 18.3% Cash & Cash EPS PAT Equivalents* * Cash & Cash Equivalents include other bank balances 6
Slide 8: Key Metrics: Q2 FY27
Key Metrics: Q2 FY27 Total Income EBIDTA & EBIDTA PAT & PAT Margin Basic EPS (In ₹) (In ₹ Mn) Margin (In ₹ Mn, %) (In ₹ Mn, %) EBIDTA EBIDTA Margin PAT PAT Margin 9.9% 10.5% 3.5% YoY YoY YoY 19.1% 18.6% 17.9% 5 36.4% 35.5% 35.3% 1,045 1,129 1,149 369 411 408 199 210 206 4.5 4.7 4.6 0 Q2FY26 Q1FY27 Q
Slide 9: Key Metrics: H1 FY27
Key Metrics: H1 FY27 Total Income EBIDTA & EBIDTA PAT & PAT Margin Basic EPS (In ₹) (In ₹ Mn) Margin (In ₹ Mn, %) (In ₹ Mn, %) EBIDTA EBIDTA Margin PAT PAT Margin 11.8% 13.2% 7.3% YoY YoY YoY 40% 35.5% 35% 30% 36.0% 25% 19.0% 18.3% 20% 15% 2,038 2,278 723 819 388 417 8.7 9.3 10% H1FY26 H1FY27 H1FY26
Slide 10: Profit & Loss Statement
Profit & Loss Statement Particulars (₹ Mn) Q2 FY27 Q1 FY27 QoQ(%) Q2 FY26 YoY (%) H1 FY27 H1 FY26 YoY (%) Revenue from Operations 1,120 1,091 1,018 2,211 1,994 Other Income 29 38 27 67 44 Total Income 1,149 1,129 1.8% 1,045 9.9% 2,278 2,038 11.8% Material and Testing Costs 262 226 201 488 389 Cost o
Slide 11: Financial Track Record
Financial Track Record TOTAL INCOME (₹ Mn) PROFITABILITY (₹ Mn) EBITDA & EBITDA PAT & PAT Margin Margin 19% 36% 36% 36% 19% 18% 31% 33% 17% 29% 15% 15% 10.5% 16.2% 17.0% CAGR CAGR CAGR (FY22-FY26) (FY22-FY26) 2,797 3,216 2,923 3,482 4,163 2,278 (FY22-FY26) 817 984 977 1,262 1,489 819 413 482 488 668
Slide 12: Shareholding Pattern
Shareholding Pattern Shareholding as on 30th September 2026 Share Information as on 30th September 2026 NSE Ticker VIMTALABS BSE Ticker 524394 Market Cap (INR Cr) 2,694.95 % free-float 64.36% Others Promoters 58.81% 35.64% Free-float market cap (INR Cr) 1,734.42 Total Debt (INR Mn) 144.34 Cash & Cas
Slide 13: Company Overview
Company Overview Section • Vimta at a Glance 02 • • Our Journey Our Offerings • Geographical Presence • Management 12
Slide 14: Vimta at a Glance
Vimta at a Glance Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high-quality, cutting-edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics, sma
Slide 15: Our Journey
Our Journey Infrastructure People Investment Capabilities Revenues Pharma & Biopharma: Discovery & development 2024 ~600,000 ft2 1300+ 492 M services; Food; Environment; Electronics Testing 3,223 M Analytical – Pharma, Biopharma & Food; Clinical 2015 400,000+ ft2 1000+ 580 M Research; Preclinical; C
Slide 16: Our offerings
Our offerings Drug discovery and development services Food, Agri & Environmental Testing Electronics & Electricals Testing 15
Slide 17: Drug discovery and development services
1. Drug discovery and development services Offerings Pharma Analytical Clinical Research Preclinical Research Pharmaceuticals, Biologics, Medical Industry Pharmaceuticals, Biologics, Nutraceuticals, Medical Devices, Animal Health Device, Agrochemical, Speciality Chemicals Accreditations & DCA, USFDA
Slide 18: Biologics - Contract Research & Development Services
2. Biologics - Contract Research & Development Services Offerings Process Development Product Development Industry Biotech & Biopharma Requirements & Small scale Non GMP (R&D) ICH Guidelines (Q2, Q6B, etc.) Compliant guidelines Process and Product Development – DS & DP o Cell Line Development o Down
Slide 19: Food, Agri & Environmental Testing
3. Food, Agri & Environmental Testing Industry Food Manufacturing & Processing industries, Cultivation, Export, Retail, Nutraceuticals, Agro-chemicals, Water & Beverages, Animal Feed and post project monitoring services for various industries viz., Oil & Gas, Power, Cement, Mining, Infrastructure, e
Slide 20: Electricals & Electronics Testing & Certification
4. Electricals & Electronics Testing & Certification Industry Aviation, Defence, Medical Device, Telecom, Home appliances, Toys, Industrial & control equipment, Consumer electronics, Rail & Automotive, IT, IOT, physical security products, and allied industries No. of Locations 2 (Hyderabad) Accredit
Slide 21: Geographical Presence
Geographical Presence Food & Pharma Environment Electrical and Electronics Hyderabad Hyderabad Hyderabad Ahmedabad Noida Mumbai (NFL) Nashik Bengaluru Nellore Kolkata Pharma Electronics & Electrical Hyderabad (Headquarters) Food & Environment 20
Slide 22: Key Management Team
Key Management Team Harriman Vungal S P Vasireddi Harita Vasireddi Sreenivas Neerukonda Siva Kambhampati Executive Director - Executive Chairman Managing Director Executive Director Chief Financial Officer Operations • Dr. S P Vasireddi is a Scientist – • Harita has close to 3 decades • Sreenivas’s
Slide 23: Industry Landscape
Industry Landscape Section • Market Opportunity 03 • Factors Driving Industry Growth 22
Slide 24: Markets Opportunity (Global)
Markets Opportunity (Global) Pharmaceutical Electronics Preclinical Food Testing Analytical Testing Testing 15,700 5,500 48,000 25,581 (USD Mn) 10,500 3,700 Global 26,300 17,962 2026 | 2031 2026 | 2031 2025 | 2033 2025 | 2033 23
Slide 25: Markets Opportunity (Indian)
Markets Opportunity (Indian) Pharmaceutical Electronics Preclinical Food Testing Analytical Testing Testing 780 451 1,510 15,300 (USD Mn) Indian 368 215 718 9,190 2025 | 2035 2025 | 2033 2025 | 2033 2025 | 2035 24
Slide 26: Factors Driving Industry Growth
Factors Driving Industry Growth • Shift towards complex generics & biosimilars • Surge in demand for certification services of electrical & electronic • Rising demand for innovation, biologics & products, growing defence budgets peptides and make in India initiatives • India’s pharmaceutical export
Slide 27: Our Competitive Advantage
Our Competitive Advantage Section • Our Position in the CRTO Landscape 04 • Our Strength 26
Slide 28: Our Position in the CRTO Landscape
Our Position in the CRTO Landscape Pharma Analytical Clinical Research Electronics & Electricals • #1 in India • Among the most reputed CROs in • One of the leading labs in • Customers – 90% of India top 20 India Southern India • 40% revenues from overseas • 75% of revenues from overseas Food & Envi
Slide 29: Our Strengths
Our Strengths Infrastructure Innovations Knowledge Unparalleled lab Continuous addition Multi-disciplinary, infrastructure in the of services and skilled and trained country. Gold LEED evolving excellence manpower certified Vivarium Facilities with scalable capacities Customer Centricity Compliance
Slide 30: Way Forward
Way Forward Section • Our Key Growth Drivers & Strategies 05 29
Slide 31: Our Key Growth Drivers & Strategies
Our Key Growth Drivers & Strategies Favourable Core business Core operational Best markets strategies strategies practices Growth momentum Capacity expansions Operational excellence Good corporate governance in markets Service innovations Hiring right talent Risk management Growing d
Slide 32: Thank You
THANK YOU Vimta Labs Ltd. Registered Office Siva Kambhampati | Chief Financial Officer #142, IDA Phase 2, Cherlapally, [email protected] Hyderabad Telangana, India. 500051 Ernst & Young Siddesh Chawan Advait Bhadekar NSE: VIMTALABS ISIN: INE579C01029 [email protected] Advait.Bhadekar